"5-fluorouracil (5-FU) je pou\u017E\u00EDv\u00E1n k adjuvantn\u00ED (postopera\u010Dn\u00ED) a neodjuvantn\u00ED (p\u0159edopera\u010Dn\u00ED) cytostatick\u00E9 l\u00E9\u010Db\u011B kolorekt\u00E1ln\u00EDho karcinomu. D\u00E1vka je obvykle ur\u010Dena podle povrchu t\u011Bla (mg/m2), a\u010Dkoliv je zn\u00E1mo, \u017Ee nebyl dosud prok\u00E1z\u00E1n line\u00E1rn\u00ED vztah mezi d\u00E1vkou a syst\u00E9movou clearance 5-FU. Kineticky \u0159\u00EDzen\u00E1 l\u00E9\u010Dba, zalo\u017Een\u00E1 na AUC (plocha pod k\u0159ivkou plazmatick\u00FDch koncentrac\u00ED v \u010Dase po startu kontinu\u00E1ln\u00ED i.v. inf\u00FAze), kter\u00E1 dob\u0159e koreluje s toxicitou, byla zat\u00EDm vyvinuta jen pro terapii adjuvantn\u00ED." . "Hroch, Milo\u0161" . . "5-fluorouracil (5-FU) is used for adjuvant(postoperative) and neoadjuvant (preoperative) cytostatic therapy of colorectal cancer. Dose is usually determined by body surface (mg/m2) in spite of the fact that a linear relationship between the dose and systemic clearance has not been proven so far. Kinetically guided therapy has only been developed for adjuvant therapy based on AUC (area under the curve of plasma concentrations in time after the start of 5-FU i.v.infusion) that is well correlated with toxicity."@en . "[2A9CED877C09]" . "P(NS9693)" . "Pozn\u00E1mky k inovac\u00EDm v cytostatick\u00E9 terapii 5-fluorouracilem"@cs . . "Klinick\u00E1 farmakologie a farmacie" . . . "CZ - \u010Cesk\u00E1 republika" . . "Pozn\u00E1mky k inovac\u00EDm v cytostatick\u00E9 terapii 5-fluorouracilem" . . "222297" . "2" . "1212-7973" . "Pozn\u00E1mky k inovac\u00EDm v cytostatick\u00E9 terapii 5-fluorouracilem"@cs . "Grim, Ji\u0159\u00ED" . . "11150" . "25" . "Mart\u00EDnkov\u00E1, Ji\u0159ina" . . "Pozn\u00E1mky k inovac\u00EDm v cytostatick\u00E9 terapii 5-fluorouracilem" . . . "5"^^ . . "Comments on 5-fluorouracil - based anticancer chemotherapy innovations"@en . "5-fluorouracil (5-FU) je pou\u017E\u00EDv\u00E1n k adjuvantn\u00ED (postopera\u010Dn\u00ED) a neodjuvantn\u00ED (p\u0159edopera\u010Dn\u00ED) cytostatick\u00E9 l\u00E9\u010Db\u011B kolorekt\u00E1ln\u00EDho karcinomu. D\u00E1vka je obvykle ur\u010Dena podle povrchu t\u011Bla (mg/m2), a\u010Dkoliv je zn\u00E1mo, \u017Ee nebyl dosud prok\u00E1z\u00E1n line\u00E1rn\u00ED vztah mezi d\u00E1vkou a syst\u00E9movou clearance 5-FU. Kineticky \u0159\u00EDzen\u00E1 l\u00E9\u010Dba, zalo\u017Een\u00E1 na AUC (plocha pod k\u0159ivkou plazmatick\u00FDch koncentrac\u00ED v \u010Dase po startu kontinu\u00E1ln\u00ED i.v. inf\u00FAze), kter\u00E1 dob\u0159e koreluje s toxicitou, byla zat\u00EDm vyvinuta jen pro terapii adjuvantn\u00ED."@cs . "RIV/00216208:11150/11:10099492" . . . "RIV/00216208:11150/11:10099492!RIV12-MZ0-11150___" . . . "3"^^ . . "neoadjuvant therapy; adjuvant therapy; kinetically guided individualized therapy; 5-fluorouracil"@en . . "Comments on 5-fluorouracil - based anticancer chemotherapy innovations"@en . . "3"^^ . .